Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

INTRODUCTION: Deucravacitinib, a newly approved oral medication for the treatment of patients with moderate to severe plaque psoriasis, demonstrated efficacy versus apremilast and placebo in two phase 3 randomized controlled trials (RCTs). A systematic review and network meta-analysis (NMA) indirect...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April W., Warren, Richard B., Zhong, Yichen, Zhuo, Joe, Cichewicz, Allie, Kadambi, Ananth, Junqueira, Daniela, Westley, Tracy, Kisa, Renata, Daamen, Carolin, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613195/
https://www.ncbi.nlm.nih.gov/pubmed/37801281
http://dx.doi.org/10.1007/s13555-023-01034-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613195/
https://www.ncbi.nlm.nih.gov/pubmed/37801281
http://dx.doi.org/10.1007/s13555-023-01034-7

Ejemplares similares